NEBIVOLOL HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H25F2NO4.ClH
Molecular Weight	441.896
Optical Activity	( + / - )
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.[H][C@]1(CCC2=CC(F)=CC=C2O1)[C@H](O)CNC[C@@H](O)[C@@]3([H])CCC4=C(O3)C=CC(F)=C4

InChI

InChIKey=JWEXHQAEWHKGCW-VCVZPGOSSA-N

InChI=1S/C22H25F2NO4.ClH/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22;/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2;1H/t17-,18-,21-,22+;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C22H25F2NO4
Molecular Weight	405.435
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugbank.ca/drugs/DB04861 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_LBL.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18485134 | https://www.ncbi.nlm.nih.gov/pubmed/9825177 | https://www.ncbi.nlm.nih.gov/pubmed/21283024 | https://www.ncbi.nlm.nih.gov/pubmed/1681809 | https://www.ncbi.nlm.nih.gov/pubmed/1357130https://www.drugbank.ca/drugs/DB04861 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_LBL.pdf | http://www.bystolic.com/

Nebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothelium-dependent arterial relaxation in a dose dependent manner, by stimulation of the release of endothelial nitric oxide. Nitric oxide acts to relax vascular smooth muscle cells and inhibits platelet aggregation and adhesion. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors. Marketed under the brand name BYSTOLIC, Nebivolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2455841 \| https://www.ncbi.nlm.nih.gov/pubmed/2462161 \| https://www.allergan.com/assets/pdf/bystolic_pi \| https://www.ncbi.nlm.nih.gov/pubmed/11309254	Antagonist 2778		0.7 nM [Ki]
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21283024 \| https://www.ncbi.nlm.nih.gov/pubmed/1681809	Antagonist 2778		0.35 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 567 Sources: https://www.allergan.com/assets/pdf/bystolic_pi https://www.drugs.com/pro/nebivolol.html https://www.ncbi.nlm.nih.gov/pubmed/19393838	Primary		Approved 8429	BYSTOLIC Approved Use BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. BYSTOLIC may be used alone or in combination with other antihypertensive agents . Launch Date 2007
Hypertension 567 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7596131 https://www.ncbi.nlm.nih.gov/pubmed/7692155 https://www.ncbi.nlm.nih.gov/pubmed/18485134 https://www.ncbi.nlm.nih.gov/pubmed/1357130	Primary		Approved 8429	BYSTOLIC Approved Use BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. BYSTOLIC may be used alone or in combination with other antihypertensive agents . Launch Date 2007

C_max

Value	Dose	Co-administered	Analyte	Population
1.48 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
7.76 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11 h REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	unknown		NEBIVOLOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	Disc. AE: Hyperhidrosis, Pallor... AEs leading to discontinuation/dose reduction: Hyperhidrosis Pallor Depressed level of consciousness Hypokinesia Hypotension Sinus bradycardia Hypoglycemia Hypokalemia Respiratory failure Vomiting Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	unhealthy n = 6545 Health Status: unhealthy Condition: Hypertension Population Size: 6545 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache (0.4%) Nausea (0.2%) Bradycardia (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Co-administed with:: valsartan, oral(80 mg, qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1	Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1

AEs

AE	Significance	Dose	Population
Depressed level of consciousness	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hyperhidrosis	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hypoglycemia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hypokalemia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hypokinesia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Hypotension	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Pallor	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Respiratory failure	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Sinus bradycardia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Vomiting	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Co-administed with:: acetylsalicylic acid, oral(>100 mg) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8	healthy n = 1 Health Status: healthy Population Size: 1 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.8
Bradycardia	0.2% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	unhealthy n = 6545 Health Status: unhealthy Condition: Hypertension Population Size: 6545 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4
Nausea	0.2% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	unhealthy n = 6545 Health Status: unhealthy Condition: Hypertension Population Size: 6545 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4
Headache	0.4% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4	unhealthy n = 6545 Health Status: unhealthy Condition: Hypertension Population Size: 6545 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf Page: p.4
Disorder fetal	Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Co-administed with:: valsartan, oral(80 mg, qd) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Hypertension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf Page: p.1

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737	inhibitor 1767	substrate 1217 inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP3A4/5 278

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP3A4/5 335	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 28, 50, 55	minor
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206302Orig1s000ClinPharmR.pdf Page: 17.0	yes		yes (co-administration study) Comment: from product label: fluoxetine coadministration led to increased AUC by 8% and Cmax by 3-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206302Orig1s000ClinPharmR.pdf Page: 17.0

Sourcing

Vendor/Aggregator	ID	URL
AChemBlock	10241
AK Scientific	M753
Aronis	BBC/719
BOC Sciences	118457-15-1
IBScreen	BB_SC-12513
IBScreen	Bio-0068
Lab Network	LN01346236
MolPort	MolPort-003-849-342
MolPort	MolPort-023-276-830
ShangHai Biochempartner	BCP21038
Tocris	3517
Toronto Research Chemicals	N387896
Vitas-M Laboratory	STK637549
ZINC	ZINC000003951631	http://zinc15.docking.org/substances/ZINC000003951631
eMolecules	29703203
eMolecules	300435536
eMolecules	30387256
mcule	MCULE-7932280679

PubMed

Title	Date	PubMed
Relationship between the sympatholytic action of nebivolol and hypotension.	1992 Jul	1383620
Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol.	1993 Aug	7692155
[Effect of enape combined with nebilet in hypertension].	2002	12587324
[Effect of nebivolol on dynamics of microalbuminuria, renal blood flow and 24-hour blood pressure profile in patients with hypertension].	2002	12494075
[Effect of nebivolol on remodeling of the heart and vessels and the state of hemodynamics in patients with hypertension].	2002	12494053
[Assessment of safety and antihypertensive efficacy of a cardioselective beta-blocker nebivolol in patients with hypertension and concomitant chronic obstructive bronchitis].	2002	12494034
[Antihypertensive efficacy and tolerability of nebivolol].	2002	12494015
[Autonomic nervous system function and effects of beta-adrenoblockers on heart rhythm variability in patients with myocardial infarction].	2002	12416220
[Beta blocker in endothelial dysfunction. Growth of blood vessel cells is halted].	2002 Aug 22	12380150
Gateways to clinical trials.	2002 Dec	12616965
Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study.	2002 Dec	12453547
[Beta blocker enhances NO liberation in the endothelium. Vascular tone long-term improvement].	2002 Dec 5	12577747
[Cardiac protection by beta-1 selective beta blocker. Still better in the 3rd generation?].	2002 Jul 11	12198891
Nebivolol ameliorates nitric oxide deficient hypertension.	2002 Jun 20	12806161
[Despite antihypertensive treatment with beta-blocker patients remain incapacitated].	2002 May 2	12422716
Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design.	2002 Nov	12243852
[Beta blockade plus NO release. Patients with heart failure can be loaded more].	2002 Oct 10	12474368
Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP.	2002 Sep	12223177
Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms.	2002 Sep	12223176
Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress.	2002 Sep	12195121
Focus on small artery stiffness.	2002 Sep	12195105
[Heart rate control with nebivolol in patients with tachysystolic atrial fibrillation].	2003	14593370
[The use of nebivolol in menopausal women with hypertension].	2003	14593358
[Dynamics of a 24-h profile of arterial pressure and function of the vascular endothelium in nebivolol treatment of hypertensive patients].	2003	14520947
[Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].	2003	12934313
[Effect of nebivolol on the state of pituitary-gonadal system and lipid peroxidation in young and middle aged men with hypertension].	2003	12891274
[Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes].	2003	12891271
[Use of nebivolol in patients with mild and moderate hypertension].	2003	12718224
[Hemodynamic effects of the beta blocker nebivolol].	2003 Apr	12914405
Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.	2003 Apr	12658024
Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells.	2003 Apr 1	12692005
Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta.	2003 Aug	12883327
Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension.	2003 Aug 1	12888152
Lack of inverse agonistic activity of nebivolol, its D- and L-enantiomers and of in vivo metabolized nebivolol in human myocardium.	2003 Aug 22	12969754
Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.	2003 Dec	14761075
[Beta blocker improves the endothelial function. Gas-forming blood vessel protection].	2003 Dec 18	14974334
Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies.	2003 Jan 26	12535855
The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.	2003 Jun	12808486
A comparison of the beta1-selectivity of three beta1-selective beta-blockers.	2003 Jun	12795776
Different effect of antihypertensive drugs on conduit artery endothelial function.	2003 Jun	12719441
Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action.	2003 Jun 3	12742996
Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).	2003 May	14574084
Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.	2003 May	12800985
[Initial data on nebivolol in heart failure. Beta blockers strengthen older hearts, too].	2003 May 29	12866284
[Nebivolol in the treatment of ischemic heart disease patients with chronic heart failure].	2004	15029131
The shift in the "paradigm" of the pharmacology of hypertension.	2004	14965315
[Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].	2004 Apr 8	15054690
Antioxidant activity of nebivolol in the rat aorta.	2004 Jan	14668581
Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD.	2004 Mar-Apr	15031571
Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.	2008 Summer	18485134

Patents

Sample Use Guides

In Vivo Use Guide

After a 4-week placebo run-in period, 30 patients (mean age 48 years) were randomly allocated to double-blind treatment with either DL-nebivolol 5 mg or D-nebivolol 2.5 mg once daily for 4 weeks.

Route of Administration: Oral

In Vitro Use Guide

Nebivolol and d-nebivolol (SRRR) inhibited noradrenaline-induced cAMP accumulation with IC50 values of 22 and 15 nM, respectively in rat living cardiac cells.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:52:12 GMT 2023` Edited by `admin` on `Fri Dec 15 15:52:12 GMT 2023`
Record UNII	JGS34J7L9I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NEBIVOLOL HYDROCHLORIDE

Official Name

English

BYSTOLIC

Brand Name

English

BYVALSON COMPONENT NEBIVOLOL HYDROCHLORIDE

Brand Name

English

NEBIVOLOL HYDROCHLORIDE [USP-RS]

Common Name

English

(1RS,1'RS)-1,1'-((2RS,2'SR)-BIS(6-FLUORO-3,4-DIHYDRO-2H-1-BENZOPYRAN-2-YL))-2,2'-IMINODIETHANOL HYDROCHLORIDE

Common Name

English

NEBIVOLOL HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

NEBIVOLOL HYDROCHLORIDE [MART.]

Common Name

English

R067555

Code

English

2H-1-BENZOPYRAN-2-METHANOL, .ALPHA,.ALPHA.'-(IMINOBIS(METHYLENE))BIS(6-FLUORO-3,4-DIHYDRO-, HYDROCHLORIDE, (.ALPHA.R,.ALPHA.'R,2R,2'S)-REL-

Common Name

English

Nebivolol hydrochloride [WHO-DD]

Common Name

English

R-067555

Code

English

NEBIVOLOL HYDROCHLORIDE [USAN]

Common Name

English

NEBIVOLOL HCL

Common Name

English

NEBIVOLOL HYDROCHLORIDE COMPONENT OF BYVALSON

Brand Name

English

NEBIVOLOL HYDROCHLORIDE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576